---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Diagnosis"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Diagnosis. Topics: Estrogen receptor testing by immunohistochemistry, HER2 testing and the distinction between immunohistochemistry 0 and 1+, Biopsy of metastatic disease and reassessment of receptor status, Biopsy guidance for bone-only metastatic presentation, and 11 further topics. 15 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/diagnosis"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Diagnosis

<a id="heading-2.2.1.5"></a>

## 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

### Estrogen receptor testing by immunohistochemistry

> “The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose.”
> “Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive.”
> “Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment.”
> “A sample is considered ER negative if < 1% or 0% of tumor cell nuclei are immunoreactive.”

Source: [Allison et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31928404/)

<a id="topic-2.2.1.5-2"></a>

### HER2 testing and the distinction between immunohistochemistry 0 and 1+

> “The 2018 ASCO-CAP recommendations for HER2 testing are affirmed.”
> “This update acknowledges a new indication for trastuzumab deruxtecan when HER2 is not overexpressed or amplified but is immunohistochemistry (IHC) 1+ or 2+ without amplification by in situ hybridization.”
> “Therefore, while it is premature to create new result categories of HER2 expression (eg, HER2-Low, HER2-Ultra-Low), best practices to distinguish IHC 0 from 1+ are now clinically relevant.”

Source: [Wolff et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37284804/)

<a id="topic-2.2.1.5-3"></a>

### Biopsy of metastatic disease and reassessment of receptor status

> “At first diagnosis of MBC, a biopsy is recommended to confirm histology and re-assess tumour biology, if feasible”
> “In case of important differences in ER, PgR and HER2 status between the primary tumour and recurrence, patients can generally be managed according to the receptor status of the recurrent disease biopsy [V, B].”
> “In patients who are not candidates for ET, re-assessment of HER2 status by immunohistochemistry and/or in situ hybridisation (HER2-low, -ultralow or -0) is recommended [I, A; ESCAT score: I-A].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.1.5-4"></a>

### Biopsy guidance for bone-only metastatic presentation

> “All patients with newly diagnosed lesions should have a biopsy, if clinically feasible, to confirm the presence of breast cancer and to assess the subtype of the recurrence.”
> “Biological markers (especially ER and HER2) should be reassessed at least once in the metastatic setting, even in case of a bone-only metastatic presentation.”
> “If a bone lesion is the biopsy site, it is preferable to biopsy a mixed lytic and sclerotic lesion rather than a pure sclerotic area to increase the chance of retrieving adequate high-quality cells to assess.”

Source: [Cardoso et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11231614/)

<a id="topic-2.2.1.5-5"></a>

### ASCO recommendation for ESR1 testing at recurrence or progression

> “To aid in treatment selection, the Expert Panel recommends routine testing for emergence of ESR1 mutations at recurrence or progression on ET (given with or without CDK4/6 inhibitor) in patients with ER-positive, HER2-negative MBC.”
> “Testing with a Clinical Laboratory Improvement Amendments–certified assay should be performed on blood or tissue obtained at the time of progression, as ESR1 mutations develop in response to selection pressure during treatment and are typically undetectable in the primary tumor.”
> “Blood-based ctDNA is preferred owing to greater sensitivity.”
> “Patients whose tumor or ctDNA tests remain ESR1 wild-type may warrant retesting at subsequent progression(s) to determine if an ESR1 mutation has arisen”

Source: [Burstein et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.23.00638)

<a id="topic-2.2.1.5-6"></a>

### ESMO recommendation for ESR1 and PI3K pathway testing

> “Evaluation of ESR1 mutations [circulating tumour DNA (ctDNA) or tumour tissue] is recommended in ER-positive, HER2-negative MBC following progression on an aromatase inhibitor (AI) with or without a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor [I, A; ESCAT score: I-A].”
> “Evaluation of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) pathway alterations (PIK3CA, PTEN and AKT1 mutations) using ctDNA or metastatic or primary tumour biopsies is recommended in ER-positive, HER2-negative MBC, mainly in the endocrine-resistant setting, if specific treatments are available [I, A; ESCAT score: I-A].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.1.5-7"></a>

### ABC8 recommendation for plasma ctDNA testing for ESR1 at progression

> “The recommendation to test blood ctDNA at disease progression, provided that a targeted treatment is available, is consistent with the biology of ESR1 mutations as acquired mechanisms of endocrine resistance, their enrichment after aromatase inhibitor exposure, and the fact that plasma may better capture their polyclonal emergence than a single tissue biopsy.”
> “The recommendation to consider tissue testing when plasma is negative, and to repeat testing under continued endocrine-based therapy if the result would influence treatment choice, is clinically sound”
> “We do not recommend ctDNA assessment for the demonstration of disease progression, while recognizing that ctDNA is an appropriate option to detect actionable genomic alterations for treatment selection.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.1.5-8"></a>

### Multigene panels on plasma or tissue

> “now explicitly supporting the use of multigene assays performed on plasma ctDNA and/or tissue, not only to facilitate enrollment into clinical trials but also to identify clinically actionable alterations, particularly ESR1 mutations and alterations in the PIK3CA/AKT/PTEN pathway”
> “in particular, plasma is preferred for ESR1 testing”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.1.5-9"></a>

### Timing of tissue and liquid biopsy along the treatment course

> “Our study suggests obtaining TBx for CGP at time of de novo/recurrent diagnosis, followed by LBx for detecting acquired GA in 2nd + lines.”
> “Reflex TBx should be considered when ctDNA TF < 1%.”

Source: [Bhave et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11420341/)

<a id="topic-2.2.1.5-10"></a>

### Detection technologies and polyclonality of ESR1 mutations

> “Sample sources include solid tissue biopsy, CTCs, and cell-free DNA (cfDNA); detection assays include next-generation sequencing (NGS) and droplet digital PCR (ddPCR), with ddPCR the most sensitive”
> “Thus, subclonality, polyclonality, and distinct effects of different ESR1 mutations demonstrate the utility inherent in liquid biopsy as compared to solid tissue sampling in characterizing the tumor ecosystem.”

Source: [Brett et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8365900/)

<a id="topic-2.2.1.5-11"></a>

### PIK3CA testing in plasma with tissue reflex

> “Candidates for a regimen with a phosphatidylinositol 3-kinase inhibitor and hormonal therapy should undergo testing for PIK3CA mutations using next-generation sequencing of tumor tissue or circulating tumor DNA (ctDNA) in plasma to determine eligibility for alpelisib plus fulvestrant.”
> “If no mutation is found in ctDNA, testing in tumor tissue, if available, should be used.”

Source: [Henry et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35759724/)

<a id="topic-2.2.1.5-12"></a>

### Companion diagnostic: Guardant360 CDx for ESR1 mutations

> “Guardant360 CDx utilizes circulating cell-free DNA (cfDNA) from plasma of peripheral whole blood collected in Streck Cell-Free DNA Blood Collection Tubes”
> “The current panel-track supplement was submitted to expand the intended use and indications for use of Guardant360® CDx to include a companion diagnostic indication for the detection of specific ESR1 mutation(s) (SNVs and V422 deletion) in patients with breast cancer who may benefit from treatment with INLURIYO (imlunestrant).”
> “Missense mutations between codons 310 and 547 of ESR1 will be reported in Category 1 as a companion diagnostic (CDx) for patients with breast cancer for ORSERDU (elacestrant).”
> “A negative result from a plasma specimen does not assure that the patient’s tumor is negative for genomic findings.”

Source: [FDA Guardant360 CDx SSED S021 (2025)](https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200010S021B.pdf)

<a id="topic-2.2.1.5-13"></a>

### Imaging for baseline staging

> “Computed tomography (CT) of the chest and abdomen and bone scintigraphy can be recommended as the minimum imaging work-up for baseline staging, as well as blood tests, including liver function tests [II, B].”
> “[18F]2-fluoro-2-deoxy-d-glucose–positron emission tomography (PET)–CT can also be recommended [II, B].”
> “CT or X-ray can be recommended for evaluation of impending fracture risk [V, B].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.1.5-14"></a>

### Brain imaging

> “Brain imaging cannot be recommended for asymptomatic patients at initial MBC diagnosis or during disease monitoring [V, D].”
> “Brain imaging is recommended for symptomatic patients [II, A]. MRI can be recommended as the preferred technique [II, B].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.1.5-15"></a>

### Response evaluation during treatment

> “Evaluation of response can be recommended every 2-4 months depending on patient symptoms, disease dynamics, location, extent of metastasis and type of treatment [V, B].”
> “Repeat bone scans may be considered for bone-only and bone-predominant metastases, noting that interpretation may be confounded by a possible flare during the first few months of treatment [III, C].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

Additional sources: [Bello et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42002527/); [Cabel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41260263/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
